

Pleasance, E.D., Cheetham, R.K., Stephens, P.J., McBride, D.J., Humphray, S.J., Greenman, C.D., Varela, I., Lin, M.L., Ordóñez, G.R., Bignell, G.R., et al. (2010). *Nature* 463, 191–196.

van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., Frankhuizen, W.S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J.T., Koop, K., van der

Kooi, A.J., Goemans, N.M., et al. (2007). *N. Engl. J. Med.* 357, 2677–2686.

Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjöblom, T., Leary, R.J., Shen, D., Boca, S.M., Barber, T., Ptak, J., et al. (2007). *Science* 318, 1108–1113.

Xu, X., Yang, D., Ding, J.H., Wang, W., Chu, P.H., Dalton, N.D., Wang, H.Y., Bermingham, J.R., Jr., Ye, Z., Liu, F., et al. (2005). *Cell* 120, 59–72.

Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011). *Nature*. Published online September 11, 2011. 10.1038/nature10496.

Resistance to EGFR-Targeted Therapy: A Family Affair

Gregory Vlacich¹ and Robert J. Coffey^{2,3,*}

¹Department of Radiation Oncology

²Department of Medicine and Cell and Developmental Biology

Vanderbilt University, Nashville, TN 37232-2279, USA

³Department of Veterans Affairs Medical Center, Nashville, TN 37212-2637, USA

*Correspondence: robert.coffey@vanderbilt.edu

DOI 10.1016/j.ccr.2011.10.006

The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of *ERBB2* or increased levels of the ERBB3/ERBB4 ligand heregulin.

The advent of targeted biologic agents has revolutionized treatment for many types of cancer by focusing therapy on specific aberrant signaling pathway components. One such target, the epidermal growth factor receptor (EGFR, or ERBB1), is overexpressed in many cancers, including colorectal (CRC), head and neck, bladder, and nonsmall cell lung cancer (NSCLC), and overexpression correlates with poor outcomes. Cetuximab, a monoclonal antibody directed against the ligand-binding domain of the EGFR, can inhibit cell growth and survival in a number of malignancies, and it is currently approved by the FDA for the treatment of head and neck squamous cell carcinoma and metastatic CRC.

Unfortunately, treatment response to cetuximab has not been uniform because a subset of patients shows poor response up front, whereas others develop resistance after initial benefit. Well-established causes of de novo cetuximab resistance include activating mutations in *KRAS* codons 12 and 13 and *BRAF*, with the impact of *PI3KCA* and *NRAS* mutations

less clear. A recent study by Yonesaka et al. (2011) has identified a new mechanism of de novo and acquired resistance to cetuximab therapy via increased signaling through ERBB2, a member of the ErbB family of receptor tyrosine kinases. Importantly, they demonstrate that either amplification of *ERBB2* or increased levels of the ERBB3/ERBB4 ligand heregulin are present in patients with CRC that exhibited de novo or acquired cetuximab resistance.

Resistance to EGFR-targeted therapy is typically mediated through alternate means of extracellular signal-regulated kinase 1/2 (ERK1/2) activation that bypass EGFR either via alternative receptors at the plasma membrane or constitutively active downstream components. By generating cetuximab-resistant cell lines, Yonesaka et al. first identified multiple clones that exhibited less effective suppression of ERK1/2 phosphorylation in the presence of cetuximab. Further analysis of these clones revealed amplification of *ERBB2* with corresponding increases in total and phospho-ERBB2

levels. Subsequent depletion of ERBB2 in the resistant clones restored sensitivity to cetuximab, confirming the importance of ERBB2 in the resistant phenotype.

In addition to *ERBB2* amplification, Yonesaka et al. uncovered a subset of cetuximab-resistant clones where acquired resistance was mediated instead by increased levels of heregulin, a ligand that binds ERBB3 and ERBB4. These elevated levels of heregulin resulted in increased association between ERBB2 and ERBB3 and subsequent activation of downstream targets. Interestingly, this is analogous to hormone-refractory breast cancer where heregulin induces estrogen independence and metastasis in part through an increase in ERK1/2 and suspected ERBB activity (Atlas et al., 2003). The expression levels of other ERBB ligands were not addressed by Yonesaka et al., and so their potential contribution to ERBB2-mediated resistance in this experimental system is unclear. The role, if any, of these other ligands would be interesting because upregulation of some ligands may also




Figure 1. Mechanisms of Resistance to EGFR-Targeted Therapy

(A) Seven different mammalian EGFR ligands bind and activate EGFR, initiating complex signaling cascades that include activation of ERK1/2 (Proliferation) and Akt (Survival).

(B) In solid tumors, monoclonal antibodies that block EGFR ligand binding (e.g., cetuximab) or EGFR-selective tyrosine kinase inhibitors (TKIs) prevent activation of downstream-signaling components. De novo or acquired resistance to cetuximab may develop through *ERBB2* amplification and increased levels of the *ERBB3/ERBB4* ligand heregulin (Yonesaka et al., 2011), or to TKIs through *MET* amplification (Engelman et al., 2007)—in both instances, *ERBB3* is activated. Additional mechanisms of resistance to EGFR-targeted therapies may exist de novo (mutant *KRAS*, *BRAF*, *EGFRvIII*) or be selected for (*EGFR T790M*).

lead to *ERBB2* activation (and hence, cetuximab resistance), whereas upregulation of other ligands (i.e., EREG and AREG) in the pretreatment setting has been shown to correlate instead with sensitivity to cetuximab (Bertotti et al., 2011; Khambata-Ford et al., 2007).

As a complement to these in vitro results, Yonesaka and colleagues were able to demonstrate that alterations in *ERBB2* signaling correlate with acquired resistance to cetuximab in a clinical setting. Although the number of analyzed patient samples was limited, amplification of *ERBB2* and increased heregulin levels were observed after patients became nonresponsive to cetuximab therapy. Yonesaka et al. also presented more comprehensive clinical data indicating that *ERBB2* amplification and elevated heregulin play a role in de novo resistance as well. In patients with CRC treated with cetuximab, levels of serum heregulin protein and tumor heregulin mRNA, though widely variable, were significantly higher in patients with stable or progressive disease. These higher levels

of heregulin appeared to correlate with reduced progression-free and overall survival. The presence of *ERBB2* amplification in a larger patient cohort also correlated with worse overall survival. Of the 233 patients with CRC examined, approximately 5.5% showed amplification of *ERBB2*, which is analogous to the 5.2% of metastatic CRC and 3.6% of head and neck squamous cell carcinomas with *ERBB2* amplification found in other cohorts (Personeni et al., 2008; Stransky et al., 2011). Importantly, elevated heregulin or *ERBB2* amplification resulted in worse survival among patients with wild-type *KRAS* when examined independently. Overall, the specificity of these correlations is somewhat uncertain because we do not yet know if *ERBB2* amplification or elevated heregulin levels are poor prognostic factors independent of cetuximab therapy. Furthermore, data on progression-free and overall survival should be interpreted with caution because these are retrospective analyses on a heterogeneous group of patients.

In a complementary report by Bertotti et al. (2011) using 85 patient-derived CRC xenografts, *ERBB2* was amplified in 36% of *KRAS/NRAS/BRAF/PI3KCA* wild-type tumors that were resistant to cetuximab. This amplification was greatly enriched in this population because *ERBB2* was amplified in only 2.7% of unselected CRCs.

Similar to the mechanism of resistance reported by Yonesaka et al., resistance through bypass signaling is seen with other EGFR-targeted agents. In NSCLC, amplification of *MET* was associated with resistance to the reversible EGFR tyrosine kinase inhibitor gefitinib via *ERBB3* activation (Engelman et al., 2007). In *HER2 (ERBB2)* amplification-positive breast cancers, resistance to trastuzumab, a humanized antibody directed against the extracellular domain of *HER2*, can be mediated by overexpression of EGFR and EGFR ligands EGF, TGF- α , and HB-EGF (Ritter et al., 2007). These studies and that presented by Yonesaka et al. illustrate that the effectiveness of monotherapy targeting one member of the ErbB family may be compromised by compensatory upregulation or activation of another ERBB receptor or related receptor tyrosine kinases (Figure 1).

The identification of *ERBB2* as a mediator of de novo and acquired cetuximab resistance suggests that a strategy of combined targeted therapy in EGFR-driven malignancies might improve treatment outcomes in a select group of patients. In preclinical in vitro studies, combined treatment with cetuximab and an *ERBB2*-targeted agent inhibited growth of cetuximab-resistant cells (Quesnelle and Grandis, 2011; Yonesaka et al., 2011). Additionally, treatment of cetuximab-resistant, *KRAS/NRAS/BRAF/PI3KCA* wild-type, *ERBB2*-amplified patient-derived xenografts with combined EGFR and *ERBB2*-inhibition resulted in significant tumor regression (Bertotti et al., 2011). However, early clinical studies thus far with combined ERBB receptor inhibition have been more equivocal. In *ERBB2*-amplified breast cancers, combined trastuzumab and gefitinib treatment was well tolerated, but the addition of gefitinib seemed to provide no obvious benefit (Arteaga et al., 2008). Whether a strategy of combined EGFR and *ERBB2*

inhibition will prove successful in malignancies amenable to EGFR blockade remains to be seen and is the subject of ongoing clinical trials. Consideration of *ERBB2* amplification status with regard to optimal timing of treatment (i.e., up-front combination or delayed addition of *ERBB2*-targeted therapy) may provide an additional means to improve outcomes in this patient population. Ultimately, the question remains as to whether dual EGFR/*ERBB2* inhibition will itself be limited by de novo or induced upregulation of the remaining *ERBB* receptors. This answer will become more evident as we begin to examine the clinical outcome of combined EGFR and *ERBB2*-targeted therapy.

REFERENCES

- Arteaga, C.L., O'Neill, A., Moulder, S.L., Pins, M., Sparano, J.A., Sledge, G.W., and Davidson, N.E. (2008). *Clin. Cancer Res.* 14, 6277–6283.
- Atlas, E., Cardillo, M., Mehmi, I., Zahedkargaran, H., Tang, C., and Lupu, R. (2003). *Mol. Cancer Res.* 1, 165–175.
- Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011). *Cancer Discov.* Published online September 2, 2011. 10.1158/2159-8290.CD-11-0109.
- Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., Lindeman, N., Gale, C.M., Zhao, X., Christensen, J., et al. (2007). *Science* 316, 1039–1043.
- Khambata-Ford, S., Garrett, C.R., Meropol, N.J., Basik, M., Harbison, C.T., Wu, S., Wong, T.W., Huang, X., Takimoto, C.H., Godwin, A.K., et al. (2007). *J. Clin. Oncol.* 25, 3230–3237.
- Personeni, N., Fieuws, S., Piessevaux, H., De Hertogh, G., De Schutter, J., Biesmans, B., De Roock, W., Capoen, A., Debiec-Rychter, M., Van Laethem, J.L., et al. (2008). *Clin. Cancer Res.* 14, 5869–5876.
- Quesnelle, K.M., and Grandis, J.R. (2011). *Clin. Cancer Res.* 17, 5935–5944.
- Ritter, C.A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J.A., and Arteaga, C.L. (2007). *Clin. Cancer Res.* 13, 4909–4919.
- Stransky, N., Egloff, A.M., Tward, A.D., Kostic, A.D., Cibulskis, K., Sivachenko, A., Kryukov, G.V., Lawrence, M.S., Sougnez, C., McKenna, A., et al. (2011). *Science* 333, 1157–1160.
- Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011). *Sci. Transl. Med.* 3, 99ra86.